Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a Devon, Pennsylvania based clinical-stage specialty pharmaceutical company focused on creating next-generation synthetic cannabinoid therapeutics via transdermal delivery. The company’s wide ranging indications include: epilepsy, osteoarthritis, fragile X syndrome, fibromyalgia and peripheral neuropathic pain.
